Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

330
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
330
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

143
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
143
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

460
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
460
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

650
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
650
Management of Insomnia01:19

Management of Insomnia

229
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
229
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

302
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis.

Current oncology (Toronto, Ont.)·2026
Same author

Cost-effectiveness of Antibacterial Envelope for Sacral Neuromodulation Infection Prevention.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Sexual Function After Prolapse Repair and Retropubic Versus Single-incision Sling.

Urogynecology (Philadelphia, Pa.)·2026
Same author

The Administrative Burden of Overactive Bladder Medications.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Femtech Revolution for Pelvic Floor Disorders and Sexual Health.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Patient Experience Following Gynecologic Surgery Complicated by Ureteral Injury.

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Response to Letter to the Editor re: "Factors Associated With Persistent Bothersome Urinary Symptoms and Leakage After Pregnancy".

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Methodological Considerations in Postpartum Urinary Incontinence: Addressing Occupational and Clinical Confounders.

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Response to Letter to the Editor re: "Nocturnal Polyuria and MACE: Neuroendocrine Links Explaining Sex Differences" and "Nocturia and Cardiovascular Events: Risk Factor or Clinical Marker?"

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Nocturnal Polyuria and MACE: Neuroendocrine Links Explaining Sex Differences.

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Nocturia and Cardiovascular Events: Risk Factor or Clinical Marker?

Urogynecology (Philadelphia, Pa.)·2026
Same journal

Letter to the Editor re: Using Chatbot to Better Understand What Matters Most to Urogynecologic Patients.

Urogynecology (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: May 27, 2025

Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
07:56

Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases

Published on: June 28, 2024

613

Botox for Sleep Effectiveness.

Feven W Getaneh1, Lee Ann Richter2, Mai Dabbas3

  • 1From the Department of Obstetrics and Gynecology, Medstar National Center for Advanced Pelvic Surgery.

Urogynecology (Philadelphia, Pa.)
|February 19, 2025
PubMed
Summary
This summary is machine-generated.

Onabotulinum toxin A (BTX) injections significantly reduce nighttime urination in women with overactive bladder syndrome (OAB). This treatment also improves sleep quality and overall quality of life for these patients.

More Related Videos

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

19.6K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.6K

Related Experiment Videos

Last Updated: May 27, 2025

Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
07:56

Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases

Published on: June 28, 2024

613
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

19.6K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.6K

Area of Science:

  • Urology
  • Sleep Medicine
  • Quality of Life Research

Background:

  • Nocturia is a primary complaint for women with overactive bladder (OAB).
  • Preliminary studies suggest intradetrusor onabotulinum toxin A (BTX) may reduce nocturia, but its impact on sleep and quality of life is unclear.

Purpose of the Study:

  • To evaluate the efficacy of BTX injections in reducing nocturia frequency.
  • To assess the impact of BTX on sleep quality and quality of life in women with OAB.

Main Methods:

  • Prospective observational study involving adult women with OAB and at least two nocturia episodes per night.
  • Participants received BTX injections and completed bladder/sleep diaries and questionnaires at baseline and 5 weeks post-treatment.

Main Results:

  • A significant decrease in nocturia episodes (average of 2 fewer per night) was observed post-BTX.
  • Sleep disturbance reduced by 59% (P = 0.006), with significant improvements in longest sleep interval, time to first awakening, and average sleep interval.
  • Quality of life scores related to nocturia significantly improved (P < 0.001), with 40% achieving nocturia resolution (≤1 episode/night).

Conclusions:

  • Intradetrusor BTX injections are effective in reducing nighttime voids for women with OAB.
  • Treatment with BTX significantly enhances sleep quality and improves nocturia-related quality of life in this patient population.